PAC-1, the first anti-cancer agent, has shown great promise in human cancer clinical trials
2023-01-10
Scientists from the University of Illinois at Urbana-Champaign and other institutes found that PAC-1 effectively blocked tumor growth in five patients with neuroendocrine cancer and reduced tumor size in two of them in clinical trials, while also showing some therapeutic activity against sarcomas. PAC-1, a drug that stimulates programmed cell death in cancer cells, was found in phase I clinical trials to have only mild side effects in patients with advanced cancer.